Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN).

Full DD Report for ACHN

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACHN)

Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018
NEW HAVEN, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced...
Source: GlobeNewswire
Date: December, 10 2018 06:00
Achillion Pharmaceuticals beats by $0.02
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12  beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 06:03
Achillion Reports Third Quarter 2018 Financial Results
- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy - - Interim data and strategic update planned for December 17, 2018 – - September 30, 2018 cash & securities position of $283 million –  - Mary Kay Fenton to step down as CFO at ...
Source: GlobeNewswire
Date: November, 07 2018 06:00
Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries - Discovering Underlying Factors of Influence
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunOpta, Inc. (NASDAQ:STKL), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Sap...
Source: GlobeNewswire
Date: October, 17 2018 07:40
Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs
Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust...
Source: SeekingAlpha
Date: September, 26 2018 08:14
Achillion to Present at the Leerink Partners Roundtable Series
NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, Octob...
Source: GlobeNewswire
Date: September, 25 2018 06:00
Achillion to Present at the Baird 2018 Global Healthcare Conference
NEW HAVEN, Conn., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6th, 2018, at 9:05 ...
Source: GlobeNewswire
Date: August, 30 2018 06:00
Achillion appoints Dr. Steven Zelenkofske as Chief Medical Officer
Achillion Pharmaceuticals (NASDAQ: ACHN ) appoints  Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 21 2018 06:18
Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team
NEW HAVEN, Conn., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. Dr. Zelenkofske will assume responsi...
Source: GlobeNewswire
Date: August, 21 2018 06:00
Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe PLC (NASDAQ:GSM), AXT Inc (NASDAQ:AXTI), ChemoCentryx, Inc. (N...
Source: GlobeNewswire
Date: August, 20 2018 08:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-083.353.273.453.24995,198
2018-05-173.563.593.623.51888,520
2017-06-204.384.514.614.34171,909,947
2017-06-194.224.374.394.22970,214
2017-06-164.114.234.234.0652,451,532

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14234,563809,70128.9691Cover
2018-12-13151,007426,29435.4232Short
2018-12-12227,885651,86534.9589Cover
2018-12-11134,751348,72538.6410Short
2018-12-10197,990328,30460.3069Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACHN.


About Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Logo for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $496,639,659 - 05/14/2018
  • Issue and Outstanding: 138,339,738 - 05/01/2018

 


Recent Filings from (NASDAQ: ACHN)

Information for Proxy Statement under Rule 14a-101
Filing Type: DEFR14AFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 02 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ACHN)

Daily Technical Chart for (NASDAQ: ACHN)


Stay tuned for daily updates and more on (NASDAQ: ACHN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACHN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACHN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ACHN and does not buy, sell, or trade any shares of ACHN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/